Analyst Maintains Buy Rating on Regeneron Pharmaceuticals
Analyst Tazeen Ahmad has maintained a 'Buy' rating and a $1,030 price target for Regeneron Pharmaceuticals, Inc.
Stocks · News reference
Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug
Regeneron stock drops as Kodiak Sciences reports Phase 3 wAMD data showing Zenkuda rivals Eylea with extended six-month dosing schedules.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Regeneron Recognized in BioSpace 2027 Best Places to Work List
Regeneron was named among the top 20 large employers in the life sciences industry in BioSpace's 2027 Best Places to Work rankings.
Alnylam And Regeneron Says Data Published In The The New England Journal Of Medicine, Reports Up To 80% Reduction In Liver Fat Sustained For 36 Weeks After Single CIDEBsiRNA Dose In MASLD Patients
Soleo Health Named Specialty Pharmacy Partner for Regeneron's Pasatru™
Soleo Health has been selected as a specialty pharmacy partner to support the distribution and patient access for Regeneron's FDA-approved treatment, Pasatru™ (garetosmab-grts).
Soleo Health Selected as a Specialty Pharmacy Partner for Pasatru™, a New Treatment in Adults with Fibrodysplasia Ossificans Progressiva
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's newly FDA-approved treatment for fibrodysplasia ossificans progressiva (FOP). The company will provide patient access support, infusion services, and clinical coordination through its SoleoRare® division, leveraging its expertise in ultra-rare diseases.
Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain?
Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.